Stifel analysts maintained a Hold rating on ResMed stock (NYSE:RMD) with a consistent price target of $250.00. The decision comes after reviewing the company's financial performance for the second ...

RMD's stellar second-quarter fiscal 2025 results reflect the ongoing momentum and strong execution across all areas of its ...

Welcome to the Q2 fiscal-year 2025 ResMed earnings conference call. My name is Matt and I'll be your operator for today's call. (Operator Instructions) Please note that this conference call is being ...

ResMed reported robust earnings for the second quarter of fiscal 2025, surpassing expectations and showcasing strong growth ...

Respiratory health company ResMed has posted strong revenue growth and expanded margins across its global sleep and ...

January is quickly coming to a close, but there are still plenty of sales around to ensure you stick to your newfound fitness ...

U.S. surges of COVID-19, influenza, respiratory syncytial virus (RSV) and norovirus have collectively been dubbed a "quad-demic." Here what you can do.